Abstract

Dihydrolipoamide dehydrogenase (DLD) deficiency is a rare disease of genetic origin due to the malfunctioning of a shared subunit of three mitochondrial multi-enzyme complexes. Phenotypes of this disease are a set of clinical manifestations ranging from neonatal disorders to myopathy or recurrent episodes of liver failures, and vomiting for which no adequate or definitive treatment is currently available.
This study described a case involving a 16-year-old boy who had experienced recurrent vomiting of unknown cause from age two. Normal value ranges for the basic metabolic panel were reported in previous years. The patient was admitted with Wernicke’s encephalopathy after the last vomiting attack, also indicating metabolites of organic acids compatible with DLD deficiency. Whole exome sequencing identified a known pathogenic mutation in the DLD gene, leading to a diagnosis of DLD deficiency. Our patient was treated with a high dose of thiamine supplementation and continued treatment, has not experienced any vomiting attacks or related problems in the last two years and has adequately responded to the treatment prescribed.
Normal urine organic acid levels in patients with recurrent vomiting cannot roll out DLD deficiency. However, although thiamine deficiency typically induces Wernicke’s encephalopathy, it can also be implicated in pyruvate dehydrogenase complex (PDHc) deficiency, and high-dose thiamine therapy (with doses up to 30 mg/ kg) is recommended for deficient patients.

Keywords: Dihydrolipoamide dehydrogenase (DLD) deficiency, Urine organic acid, Recurrent vomiting, Wernicke encephalopathy, Thiamin supplementation References

1. Pons G, Raefsky-Estrin C, Carothers DJ, Pepin RA, Javed AA, Jesse BW, et al. Cloning and cDNA sequence of the dihydrolipoamide dehydrogenase component human alpha-ketoacid dehydrogenase complexes. Proceedings of the National Academy of Sciences. 1988;85(5):1422-6.
2. Cameron JM, Levandovskiy V, MacKay N, Raiman J, Renaud DL, Clarke JT, et al. Novel mutations in dihydrolipoamide dehydrogenase deficiency in two cousins with borderline‐normal PDH complex activity. American Journal of Medical Genetics Part A. 2006;140(14):1542-52.
3. Hong YS, Kerr DS, Craigen WJ, Tan J, Pan Y, Lusk M, et al. Identification of two mutations in a compound heterozygous child with dihydrolipoamide dehydrogenase deficiency. Human Molecular Genetics. 1996;5(12):1925-30.
4. Alfarsi A, Alfadhel M, Alameer S, Alhashem A, Tabarki B, Ababneh F, et al. The phenotypic spectrum of dihydrolipoamide dehydrogenase deficiency in Saudi Arabia. Molecular Genetics and Metabolism Reports. 2021;29:100817.
5. Shany E, Saada A, Landau D, Shaag A, Hershkovitz E, Elpeleg ON. Lipoamide dehydrogenase deficiency due to a novel mutation in the interface domain. Biochemical and biophysical research communications. 1999;262(1):163-6.
6. Quinonez SC, Thoene JG. Dihydrolipoamide dehydrogenase deficiency. 2020.
7. Odièvre MH, Chretien D, Munnich A, Robinson BH, Dumoulin R, Masmoudi S, et al. A novel mutation in the dihydrolipoamide dehydrogenase E3 subunit gene (DLD) resulting in an atypical form of α‐ketoglutarate dehydrogenase deficiency. Human Mutation. 2005;25(3):323-4.
8. Wang J, Nemeria NS, Chandrasekhar K, Kumaran S, Arjunan P, Reynolds S, et al. Structure and function of the catalytic domain of the dihydrolipoyl acetyltransferase component in Escherichia coli pyruvate dehydrogenase complex. Journal of Biological Chemistry. 2014;289(22):15215-30.
9. Patel MS, Harris RA. Mammalian α‐keto acid dehydrogenase complexes: gene regulation and genetic defects 1. The FASEB journal. 1995;9(12):1164-72.
10. Hong YS, Kerr DS, Liu T-C, Lusk M, Powell BR, Patel MS. Deficiency of dihydrolipoamide dehydrogenase due to two mutant alleles (E340K and G101del): analysis of a family and prenatal testing. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 1997;1362(2-3):160-8.
11. Naito E, Ito M, Yokota I, Saijo T, Matsuda J, Ogawa Y, et al. Thiamine-responsive pyruvate dehydrogenase deficiency in two patients caused by a point mutation (F205L and L216F) within the thiamine pyrophosphate binding region. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2002;1588(1):79-84.
12. Carrozzo R, Torraco A, Fiermonte G, Martinelli D, Di Nottia M, Rizza T, et al. Riboflavin responsive mitochondrial myopathy is a new phenotype of dihydrolipoamide dehydrogenase deficiency. The chaperon-like effect of vitamin B2. Mitochondrion. 2014;18:49-57.